This is a multiple dose, randomized, parallel, double-blind, double-dummy, multicenter and
multinational Phase III study to determine the efficacy and safety of Aclidinium bromide
400μg/Formoterol Fumarate (AB/FF) 12 μg compared to individual components and TIO
(Tiotropium) 18 μg when administered to patients with stable chronic obstructive pulmonary
disease (COPD).